Requirement for monthly heparin testing updates canceled
This article was originally published in The Gold Sheet
Executive Summary
FDA in March stopped requiring heparin manufacturers to provide the agency monthly updates on heparin test results. Last year, FDA established screening methods involving capillary electrophoresis and proton nuclear magnetic resonance to identify and remove from the market heparin that had been adulterated with oversulfated chondroitin sulfate. The agency asked all manufacturers to perform the tests and provide it with monthly updates on their results. Although FDA is no longer requiring the updates, it reminded manufacturers to continue notifying it of any positive results within three days of testing. Noting that the U.S. Pharmacopeia has added the new testing methods to its heparin monograph, FDA said its inspection program will monitor adherence to the appropriate testing regimen
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.